136 related articles for article (PubMed ID: 21770236)
1. [Application of mass spectrometry-based chromatographic technologies in the diagnosis of Alzheimer's disease].
Wang D; Xin G; Shi Z; Chen J; Li P
Se Pu; 2011 Apr; 29(4):293-7. PubMed ID: 21770236
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics.
Cui Y; Liu X; Wang M; Liu L; Sun X; Ma L; Xie W; Wang C; Tang S; Wang D; Wu Q
J Neuropathol Exp Neurol; 2014 Oct; 73(10):954-63. PubMed ID: 25192049
[TBL] [Abstract][Full Text] [Related]
3. Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.
Muguruma Y; Tsutsui H; Noda T; Akatsu H; Inoue K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():53-66. PubMed ID: 29852382
[TBL] [Abstract][Full Text] [Related]
4. Hyphenated chromatographic methods for biomaterials.
Al-Dirbashi OY; Nakashima K
Biomed Chromatogr; 2000 Oct; 14(6):406-21. PubMed ID: 11002278
[TBL] [Abstract][Full Text] [Related]
5. Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease.
Whiley L; Legido-Quigley C
Bioanalysis; 2011 May; 3(10):1121-42. PubMed ID: 21585307
[TBL] [Abstract][Full Text] [Related]
6. Determination of catecholamines and their metabolites in rat urine by ultra-performance liquid chromatography-tandem mass spectrometry for the study of identifying potential markers for Alzheimer's disease.
Lv C; Li Q; Liu X; He B; Sui Z; Xu H; Yin Y; Liu R; Bi K
J Mass Spectrom; 2015 Feb; 50(2):354-63. PubMed ID: 25800017
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease.
Shah DJ; Rohlfing F; Anand S; Johnson WE; Alvarez MT; Cobell J; King J; Young SA; Kauwe JS; Graves SW
J Alzheimers Dis; 2016; 49(2):317-27. PubMed ID: 26484917
[TBL] [Abstract][Full Text] [Related]
8. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.
Kitamura Y; Usami R; Ichihara S; Kida H; Satoh M; Tomimoto H; Murata M; Oikawa S
Neurol Res; 2017 Mar; 39(3):231-238. PubMed ID: 28107809
[TBL] [Abstract][Full Text] [Related]
9. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
Robinson RA; Amin B; Guest PC
Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
[TBL] [Abstract][Full Text] [Related]
10. Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics.
Weiner S; Blennow K; Zetterberg H; Gobom J
Expert Rev Proteomics; 2023; 20(7-9):143-150. PubMed ID: 37701966
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of 18 D-amino acids in rat plasma by an ultrahigh-performance liquid chromatography-tandem mass spectrometry method: application to explore the potential relationship between Alzheimer's disease and D-amino acid level alterations.
Xing Y; Li X; Guo X; Cui Y
Anal Bioanal Chem; 2016 Jan; 408(1):141-50. PubMed ID: 26497841
[TBL] [Abstract][Full Text] [Related]
12. A review of chromatographic methods for ketamine and its metabolites norketamine and dehydronorketamine.
Göktaş EF; Arıöz F
Biomed Chromatogr; 2018 Jan; 32(1):. PubMed ID: 28555942
[TBL] [Abstract][Full Text] [Related]
13. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers.
Wong MW; Braidy N; Poljak A; Pickford R; Thambisetty M; Sachdev PS
Alzheimers Dement; 2017 Jul; 13(7):810-827. PubMed ID: 28242299
[TBL] [Abstract][Full Text] [Related]
15. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
[TBL] [Abstract][Full Text] [Related]
16. Analytical methods to determine phytoestrogenic compounds.
Wu Q; Wang M; Simon JE
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 812(1-2):325-55. PubMed ID: 15556507
[TBL] [Abstract][Full Text] [Related]
17. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer's disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry.
Kim SH; Yang JS; Lee JC; Lee JY; Lee JY; Kim E; Moon MH
J Chromatogr A; 2018 Sep; 1568():91-100. PubMed ID: 30007793
[TBL] [Abstract][Full Text] [Related]
18. A novel strategy for rapidly and accurately screening biomarkers based on ultraperformance liquid chromatography-mass spectrometry metabolomics data.
Li C; Zhang J; Wu R; Liu Y; Hu X; Yan Y; Ling X
Anal Chim Acta; 2019 Jul; 1063():47-56. PubMed ID: 30967185
[TBL] [Abstract][Full Text] [Related]
19. A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs).
Shirotani K; Matsuo K; Ohtsuki S; Masuda T; Asai M; Kutoku Y; Ohsawa Y; Sunada Y; Kondo T; Inoue H; Iwata N
J Biochem; 2017 Dec; 162(6):391-394. PubMed ID: 28992104
[TBL] [Abstract][Full Text] [Related]
20. Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis.
Shackleton C
J Steroid Biochem Mol Biol; 2010 Aug; 121(3-5):481-90. PubMed ID: 20188832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
